Conestoga Capital Advisors raised its position in shares of Repligen Co. (NASDAQ:RGEN) by 30.4% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 866,673 shares of the company’s stock after buying an additional 201,898 shares during the period. Repligen comprises 2.0% of Conestoga Capital Advisors’ investment portfolio, making the stock its 26th largest position. Conestoga Capital Advisors owned 2.63% of Repligen worth $24,518,000 at the end of the most recent quarter.

Repligen Co. (NASDAQ:RGEN) traded up 0.98% on Friday, reaching $21.62. 117,330 shares of the company’s stock traded hands. The firm has a market capitalization of $712.23 million and a P/E ratio of 82.84. The stock has a 50-day moving average of $26.24 and a 200 day moving average of $30.97. Repligen Co. has a 52 week low of $20.54 and a 52 week high of $42.48.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.08 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.08. The firm had revenue of $19.80 million for the quarter, compared to analyst estimates of $20.50 million. Repligen’s revenue for the quarter was up 29.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.04 earnings per share. On average, equities analysts expect that Repligen Co. will post $0.39 EPS for the current fiscal year.

RGEN has been the subject of a number of research reports. Jefferies Group cut shares of Repligen from a “buy” rating to a “hold” rating in a report on Friday, November 6th. Zacks Investment Research cut shares of Repligen from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 4th.

Repligen Corporation (NASDAQ:RGEN) is a life sciences company. The Company develops, manufactures and markets bioprocessing products for life sciences and biopharmaceutical companies across the world. The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to purify monoclonal antibodies, which is a type of biologic drug. It also supplies several growth factor products and cell filtration products used to increase cell culture productivity during the bioproduction process. It has developed a series of OPUS chromatography columns for use in clinical-scale manufacturing. It manufactures and sells Protein A and growth factors to life sciences companies under supply agreements and sells chromatography columns, as well as media and quality test kits, and the Company’s Alternating Tangential Flow (ATF) products directly to biopharmaceutical companies or contract manufacturing organizations or through distributors.

12 Month Chart for NASDAQ:RGEN

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Repligen Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Co. and related companies with MarketBeat.com's FREE daily email newsletter.